INTRODUCTION
The complement system provides a first line of defense against some microorganisms and participates in innate and adaptive immune responses to many others. More than 30 plasma and cell-associated proteins in three activation pathways converge on C3 and C5 to generate C3a, C3b, C5a, and C5b-9, each of which has biological activity. The receptors (R) for C3a and C5a are rhodopsin-like class A peptide G protein-coupled sevenspan transmembrane Rs. The three extracellular loops of C3aR and C5aR1 confer ligand binding specificity while their activation is transduced through various abc G-proteins at the internal portion of the plasma membrane 1, 2 . While traditionally considered pro-inflammatory on BM-derived cells, it is clear that C3aR and C5aR1 have a more widespread distribution with a variety of effects attributable to their activation [3] [4] [5] .
As it developed, the adaptive immune system incorporated the complement system, conferring C3/C5-binding proteins to lymphocytes and dendritic cells. For example, the B lymphocyte signaling complex contains complement receptor 2, which can be activated by immune complexes (ICs) containing natural antibody, foreign antigen, and activated C3, which then facilitates adaptive humoral responses to that antigen 6 . More recent evidence has shown an important role for complement in cellular immunity. Here, it appears the T cell and its antigen-presenting dendritic cell partner generate complement activation products, with signals through C3aR and/or C5aR1 affecting T cell proliferation and differentiation in normal T cell responses, as well as in autoimmunity and alloimmunity [7] [8] [9] [10] [11] . Productive complement activation could be considered as the successful generation of biologically active C3 and C5 products. For this to occur, the system must overcome several obstacles, not the least of which is time and space; that is, many of the biologically active intermediates have a very short period of time to find the next protein partner in sequence or suffer the fate of inactivation. There are also a host of complement regulatory proteins acting throughout the pathways. Spontaneous alternative pathway activation in the fluid phase is regulated by complement factor H (FH). The zinc metalloproteinase, carboxypeptidase N (CPN), is released into serum as an active enzyme, where it potently deactivates C3a and C5a by removing their C-terminal arginine residues 12 . Carboxypeptidase B2 is present in plasma as a thrombin-activatable proenzyme, which can also cleave C3a and C5a 13, 14 . The phosphatidylinositollinked CPM is present in the kidney among other organs 15, 16 , where it potentially could also deactivate C3a and C5a.
Induction of chronic serum sickness (CSS) leads to deposition of ICs in glomeruli 17 . Despite the substantial accumulation of ICs containing iC3b and IgG Fc (i.e., ligands for b2 integrins and FccRs) wild-type C57BL/6 mice have little glomerular inflammation in CSS 18 . In contrast, FH-deficient mice with CSS uniformly develop diffuse proliferative glomerulonephritis (GN) within 5 weeks [18] [19] [20] In studies using gene-targeted mice, the significant effects of C5aR1 on the immune response could not be separated from those in inflammation. Here we attempted to surmount this by administering a cyclic peptide antagonist (ant) of C5aR1 (PMX53, (Ac)Phe-[Orn-Pro-DCha-Trp-Arg]) [23] [24] [25] beginning 2 weeks after the start of active immunization of FH 2/2 mice. Our hypothesis was effects of C5aR1 on the immune response occur in the induction phase but become insignificant in maintaining humoral immunity. We also evaluated the role for C5aR inactivation by CP, through the use of the potent CP inhibitor (inh), DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid (K i , 2 3 10 29 M) 26, 27 . These data show the importance of C5a in generating and perpetuating a humoral immune response in CSS, and the resultant IC-mediated GN.
MATERIALS AND METHODS

Experimental animals
Normal wild-type C57BL/6 mice were from Jackson Laboratories. The FH 2/2 mouse strain was generated and kindly provided by Drs Matthew Pickering and Marina Botto (Imperial College of London) 28 and continuously backcrossed onto the C57BL/6 strain in our laboratory over 10 years. Genotyping within and around FH alleles was performed using PCR-based approaches. All studies were approved by the University of Chicago and University at Buffalo Institutional Animal Care and Use Committees.
CSS protocol CSS was induced in male FH
2/2 or wild-type mice between the ages of 6-8 weeks with daily intraperitoneal administration of 4 mg horse spleen apoferritin (Calzyme Laboratories) 17, 18, [29] [30] [31] . Littermate controls received intraperitoneal injections of saline vehicle contemporaneously.
C5aR1 ant (PMX53, (Ac)Phe-[Orn-Pro-DCha-Trp-Arg], kindly provided by Dr John Lambris, University of Pennsylvania) was delivered at a dose of 25 mg/day via a mini-osmotic pump (Alzet) a regimen effective in our prior studies in lupus mice 25 . This was started 2 weeks after immunization with apoferritin had begun, at which time clinically evident disease features were present (unpublished data). The mini-osmotic pump was changed weekly. To control for peptide administration delivered via mini-osmotic pumps, a cohort of FH 2/2 mice (n 5 4) immunized with apoferritin received scrambled peptide on the same schedule. This did not affect disease features (BUN, GN scores) compared to FH 2/2 mice with CSS (n 5 13) not given peptide. As such, these data were pooled. CP inh (Plummer's reagent, DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid, Calbiochem) was administered intraperitoneally at a dose of 1 mg every 12 hours 27 starting 3 weeks after the start of daily apoferritin administration. After 5 weeks, animals were euthanized, and blood and tissues collected.
Measurements from serum
Blood urea nitrogen (BUN) concentrations were determined with a Beckman Autoanalyzer. Anti-apoferritin IgG was measured by ELISA. Polystyrene plates were coated with 5 mg/ml of apoferritin. After blocking with 1% (wt/vol) bovine serum albumin, plates were incubated with serial dilutions of serum samples or anti-horse ferritin (Jackson ImmunoResearch), followed by horseradish peroxidase-conjugated anti-mouse IgG (Kirkegaard and Perry Laboratories), and o-Phenylenediamine peroxidase substrate (Sigma-Aldrich). The data were presented as arbitrary units relative to a standard curve generated with anti-horse ferritin.
Measurements from renal tissue Tissues were fixed in 10% buffered formalin and embedded in paraffin, from which 4 mm thick sections were cut and stained with periodic acid-Schiff. Slides were scored in a blinded manner by a renal pathologist (AC) for the extent of GN on a scale of 0 to 4 (in increments of 0.5) according to the schema of Passwell et al. 32 as described previously 18, 19 . About 4 mm sections from frozen mouse kidneys were fixed in ethanol:ether (1:1) for 10 minutes followed by 95% ethanol for 20 minutes, washed with PBS and stained with fluoresceinanti-mouse C3 and rhodamine-anti-mouse IgG (Cappel, MP Biomedicals). Slides were viewed with an Olympus BX-60 IF microscope. Representative photomicrographs were taken at identical settings with a Hamamatsu EM-CCD camera. Merged images were generated with NIH Image J software.
Statistics
Data were analyzed using Minitab statistical software (v. 16, College Park, MD, USA). Data sets were first analyzed with the Anderson-Darling normality test and considered parametric with Ha . 0.05. Parametric and non-parametric data are presented as mean 6 SEM and median (Q1-Q3), respectively. All data presented graphically are from individual animals. Parametric data were analyzed by one-way ANOVA with comparisons among groups using Tukey's method. Non-parametric data sets were analyzed comparably by Kruskal-Wallis and Mood's Median testing. Potential correlations among variables were first examined by calculating the Pearson product moment; those significant were further examined using the least-squares method.
RESULTS
Contrasting effects of inhibiting C5aR1 and CP on ICGN
We generated CSS by actively immunizing C57BL/6 FH 2/2 mice with a daily intraperitoneal dose of 4 mg horse spleen apoferritin (n 5 36). As controls, FH 2/2 mice were treated identically, except apoferritin was omitted from the injections (n 5 13). After 2 weeks of apoferritin administration, some mice received C5aR1 ant (n 5 7), CP inh (n 5 8), or both (n 5 4) until the conclusion of the study after 5 weeks of apoferritin or saline administration.
As shown in Figure 1 , control FH 2/2 mice had normal renal function at the end of the 5-week experimental protocol as assessed by BUN levels of 27.9 6 1.1 mg/dl. In contrast, FH 2/2 mice with CSS induced by repetitive apoferritin immunization had impaired renal function (BUN 5 37.0 6 2.2 mg/dl). This was also true of those mice receiving CP ant (BUN 5 39.7 6 2.8 mg/dl). Renal insufficiency was prevented in FH 2/2 mice receiving C5aR1 ant for the final 3-week period, whether or not CP inh was administered (BUN 5 26.0 6 0.6 and 27.2 6 2.1 mg/dl, respectively). Thus, functional renal insufficiency in the CSS model can be prevented after disease onset by pharmacological blockade of C5aR1.
Histopathological features of ICGN were evaluated at the end of the 5-week experimental protocol ( Figure 2) . As in past studies 18, 21 a minority (4 of 13) of control FH 2/2 mice (i.e., without CSS) had some glomerular inflammation with GN scores between 0.5 and 1.5 (Figure 2A and B) . All FH 2/2 mice with CSS developed GN with 13 of 17 mice having scores of 1.5 or 2.0 (Figure 2A) . The primary histopathological feature was of diffuse hypercellularity of the glomerular tufts ( Figure 2C ). There was no evidence for thrombotic microangiopathy. As with BUN measurements, mice that received C5aR1 ant for the final 3 weeks had significantly less GN ( Figure 2D ). Here, CP inh worsened GN ( Figure 2E ), including in those mice also receiving C5aR1 ant . That the extent of GN was related to renal functional impairment is supported by the significant correlation between the two (BUN 5 25.3 1 (6.0 3 GN); r 5 0.63, P , 0.001). Thus, endocapillary diffuse proliferative GN occurring in this model relies upon C5aR1 signaling. These data illustrate that physiological complement regulation by FH and CP lessen the amount of C5a available to bind its receptor in states of IC deposition in glomeruli.
Effects of inhibiting CP on ICGN in wild-type mice
It appears when plasma FH is absent in FH 2/2 mice with CSS, there is sufficient productive generation of C5a to signal through C5aR1 19 . Given the effects of CP inh on FH 2/2 mice with CSS, we investigated whether it would affect CSS in wildtype (i.e., FH 1/1 ) mice. All control wild-type mice given saline instead of apoferritin (n 5 8) had normal BUN values (,29.0 mg/dl) and no histopathological evidence of GN. Of the mice with CSS, 3 of 5 developed mild GN (score 5 0.5) which was reflected by elevated BUN values (31.5-33.5 mg/dl). The mice with CSS also given CP inh had a small, but consistent increase in GN, with all five animals having GN scores 0.5-1.0 and BUN values o33.5 mg/dl ( Figure 3 ). As with FH 2/2 mice with CSS, GN scores and BUN values were strongly correlated (BUN 5 26.7 1 (13.1 3 GN) ; r 5 0.75, P , 0.001), supporting the relevance and interrelatedness of these two measures. These data further support the importance of both FH and CP to limit C5a generation in pathological states of IC deposition.
Contrasting effects of inhibiting C5aR1 and CP on circulating and glomerular anti-apoferritin IgG 18, FH 2/2 mice with CSS had higher sera titers of anti-apoferritin IgG than wild-type FH 1/1 mice ( Figure 4) . Interestingly, inhibition of C5aR1 from 3-5 weeks of immunization led to reduction of anti-apoferritin IgG to levels comparable to wildtype mice. Moreover, inhibition of CP led to a significant increase in anti-apoferritin IgG (Figure 4) . Thus, production of anti-apoferritin IgG in C57BL/6 mice appears to be fueled by C5a-C5aR1 in FH 2/2 mice even after the immune response has begun, which can be further increased by inhibiting CPmediated inactivation of C5a. Double-label immunofluorescence microscopy was performed to evaluate glomerular IgG and C3 ( Figure 5 ). As shown by the red staining in Figure 5B , FH 2/2 mice with CSS had IgG within mesangial regions (asterisks) with some extension to peripheral capillary walls (arrows). This was reduced in FH 2/2 mice with CSS given C5aR ant ( Figure 5C ), and worsened in mice given CP inh ( Figure 5D ). As anticipated, glomeruli from FH 2/2 mice had linear glomerular capillary wall staining for C3; this was not appreciably affected by induction of CSS or either of the inhibitors (stained green in Figure 5 ).
DISCUSSION
To model IC-mediated GN, we induced CSS through active immunization with heterologous apoferritin as originally described by Stilmant, Couser, and Cotran 29 and modified by Iskandar et al. 31 In this model, there is formation of glomerular ICs containing IgG and iC3b; these are ligands for inflammatory cell FccRs and b 2 integrins, respectively. Even in experimental conditions resulting in a large burden of glomerular ICs, C57BL/6 mice with plasma FH have little glomerular inflammation 19 . In contrast, FH 2/2 mice are uniformly susceptible to GN 18 . In the absence of plasma FH, enough C3b escapes inactivation to form C5 convertases and generate C5a 19 . This leads to C5aR1 signals that are required for inflammatory cells to react to glomerular-bound ICs 21 . Here we show mice receiving C5aR1 ant for the final 3 weeks of CSS failed to develop GN and consequent azotemia. Glomerular disease in CSS was indistinguishable between FH 2/2 mice treated with C5aR1 ant and wild-type FH 1/1 mice. Thus, blocking C5aR1 signals ''normalizes'' FH 2/2 mice. Our data allow the conclusion plasma FH is sufficient to block C5a production below that necessary for GN. Given the large burden of ICs in glomeruli in wild-type mice, we hypothesized some C3b escapes inactivation to facilitate generation of C5a; yet, the efficiency and overlapping nature of normal complement regulation was operative, with CP inactivating what C5a was generated. We confirmed this by showing treatment with CP inh exacerbated disease in wild-type mice. Even in states of considerable C5a generation, such as FH 2/2 mice with CSS, CP inactivation of C5a appears to limit disease.
Our accumulated data in CSS illustrate the tight regulation of both innate and adaptive immune systems 18, 21, 22 . Here we concentrated on the roles of FH and CP, which show the importance of signaling through C5aR1 in inflammatory disease. Downstream effects of C5aR1 include increasing FccRIII quantities 33 and a M b 2 integrin (complement receptor 3) ligand avidity 34, 35 , allowing recognition of, and activation by IgG/ iC3b-bearing ICs in the glomerulus. An elegant paradigm and supported experimentally by Gessner et al is C5aR1 activation of Ga i2 and phosphoinositide 3-kinase p110c in mononuclear phagocytes leads to a transcriptional increase in FccRIII and decrease in FccRIIB through respective gene promoter ''C5a-inductive'' and ''C5a-suppressive'' regions [36] [37] [38] . This phenomenon is relevant in experimental disease models of liver, lung, and kidney (i.e., mesangial cells); [38] [39] [40] clinically relevant is that blocking C5aR1 signals may underlie the therapeutic efficacy of intravenous immunoglobulin 41 . Thus, by altering the balance between activating and inhibitory FccRs on monocytic cells, C5aR1 can have a considerable impact on IC processing and its downstream effects.
We induce the CSS model through repetitive immunization with apoferritin without adjuvant. Animals generate an active anti-apoferritin IgG humoral immune response and deposit IgG in glomeruli, each of which can be quantified. In our prior studies, FH 2/2 mice with CSS had increased serum levels of anti-apoferritin IgG compared to wild-type controls, which we attributed to C5aR1 signaling, given equivalent anti-apoferritin IgG titers among wild-type and FH 2/2 C5aR1 2/2 mice 21 . This relationship was true for glomerular IgG as well, which was directly and positively correlated with anti-apoferritin IgG. Interestingly, here we have found comparable findings with pharmacological interventions in the final 3 weeks of the CSS model. That is, inhibiting C5aR1 led to lower serum anti-apoferritin IgG and glomerular IgG, while increasing intact C5a by blocking its inactivation by CP increased these two. While these data have been highly consistent relative to C5a/C5aR1 and FH, we must emphasize they minimize the intervening steps of IC processing involving plasma C4 and C3; erythrocytes bearing CR1 (primates) or platelets bearing FH (rodents); and FccRIII and CR3 on mononuclear phagocytes. These are highly complex, as we have found in our studies with this CSS model 17, 19, 21, 22, 42, 43 . The role for C5aR1 signaling to affect glomerular ICs was supported by studies by Falk and Jennette, in which C5-deficient mice had less glomerular ICs independent from the anti-apoferritin IgG response 30 Mesangial IgG was present in all groups with CSS (white asterisks) with some extension to the peripheral capillary walls (white arrows), but in relatively lesser amounts in FH 2/2 mice treated with C5aR ant (C) and greater amounts in those given CP inh (D), in which there was significant extension to peripheral capillary walls (double white arrows). For purposes of localization, nuclei were stained with DAPI (blue) in D. Original magnifications, 3400. become clear that C5aR1 signals are relevant to adaptive immune responses in a variety of ways. From our circumstantial data, there is an anti-inflammatory (M2) macrophage population within the kidney that appears affected by C5aR1 21 . In the active humoral immune response, signals through C5aR1 in both antigen-presenting cells and lymphocytes can promote Th1 and inhibit Treg responses 9, 10 . Perhaps because the glomerular capillary wall contains acellular portions and is exposed to relatively large quantities of plasma proteins, it is particularly at risk of complement activation. In the C3 glomerulopathies, ineffective fluid phase complement regulation allows unrestricted C3 activation and deposition of C3 products in the glomerular capillary wall [45] [46] [47] . FH also is retained by the glomerular capillary wall surface; when this is inefficient, endothelial cell injury and atypical hemolytic uremic syndrome can result [48] [49] [50] . A comparable pathophysiology is believed to occur in Bruchs membrane in the eye, accounting for the relationship between FH and age-related macular degeneration 51 . Pharmacologically targeting the complement system is now clinical reality. Because of the nature of complement activation, many inhibitors directed against a given complement protein also block successive steps in the activation pathway(s). For example, the anti-C5 antibody eculizumab prevents formation of C5a and C5b-9; the latter accounts for its therapeutic efficacy and now routine clinical use in paroxysmal nocturnal hemolgobinuria, as well as increased risks of Neisserial infections 52 . Eculizumab is highly effective, but it is also the only complement inhibitor in clinical use. Thus, it has been used in a number of past and present clinical trials, including in membranous nephropathy, lupus nephritis, atypical and Shiga-toxin-associated hemolytic uremic syndrome, C3 glomerulopathies, and anti-neutrophil cytoplasmic antigen-associated GN [53] [54] [55] , diseases with a considerable range in phenotype. Identifying which among the limited number of active complement products are pathogenic in a given disease process is not a trivial point. Blocking those not directly relevant to disease will needlessly impair normal immunity as well as potential counterregulatory (anti-inflammatory) signals, for which there is growing evidence 3 . In summary, here we studied a GN model in which the humoral immune response is directed to a continuously present foreign antigen. It is directly relevant to GN occurring in humans in infectious illnesses (e.g., Streptococcus and Hepatitis C), as well as other IC-mediated GNs such as lupus nephritis, IgA nephropathy, and membranous nephropathy; each of which is characterized by an active humoral immune response, formation of glomerular ICs, and the resulting pathological effects. We show the importance of complement regulation by both plasma FH and CP to limit the quantity of active C5a. Signaling through C5aR1 enhances the humoral immune response as well as the inflammatory response to ICs that have formed in glomeruli. Both effects are relevant even after disease has begun. Thus, pharmacological targeting of C5a in IC-mediated GN has potential clinical relevance. This could readily be accomplished by blocking C5 cleavage with eculizumab.
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